INCLUSION OF PATIENT INPUT IN VALUE AND HEALTH TECHNOLOGY ASSESSMENT
Author(s)
Desai B1, Mattingly TJ1, Subedi P2, Pham NN3, Frailer M1, Yang J1, Perfetto EM4
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Pfizer, New York, NY, USA, 3University of Washington, Seattle, WA, USA, 4National Health Council, Washington, DC, USA
Presentation Documents
OBJECTIVES : Inclusion of patient input in value and health technology assessment (V/HTA) processes is growing and evolving. However, it is unclear how solicitation and implementation of patient input is taking place across various V/HTA organizations worldwide. As healthcare globally shifts towards a patient-centered system, identifying and benchmarking current practices in V/HTA patient engagement could help to enhance improvement those practices. Our objective was to evaluate V/HTA organizations’ requirements for and use of patient input, comparing practices across U.S. value assessment organizations and ex-U.S. health technology assessment bodies. METHODS : Methods documents from 11 V/HTA organizations were screened and systematically abstracted for mentions of or requirements for patient involvement and/or input. Two reviewers evaluated each document and a third reviewer acted as tie-breaker when needed. Up to three 2018 reports for each organization were reviewed to assess actual elicitation or use of patient input and corroboration with methods documentation. RESULTS : Of 7 U.S. organizations evaluated, 2 stated patient stakeholder input was accepted and 1 provided details in a report on methods used to solicit patient input. All 4 ex-U.S. organizations stated input from patient stakeholders was accepted; however, the methods for solicitation of input were often not clear in reports. Use of patient input in V/HTA reports varied across organizations. While ICER and CADTH report using patient input to inform economic model inputs, whereas IQWIG utilizes patient input to assist with specification of patient-relevant outcomes and subgroups in the early phases of an assessment. CONCLUSIONS : It appears that, in general, U.S. value assessment organizations are lagging behind their HTA counterparts in Canada and Europe in soliciting and incorporating patient input. Good practice in V/HTA patient engagement should be identified and shared among V/HTA organizations.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Acceptance Code
HT4
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Systems & Structure, Value Frameworks & Dossier Format
Disease
No Specific Disease